At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 400 target
Drug / intervention
SYS6023drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profiles, and Preliminary Efficacy of SYS6023 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating SYS6023 for Advanced Solid Tumor. Currently recruiting, targeting 400 participants across 2 sites.
Signals
Enrolling ahead of pace
Detailed Summary
This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2025202620272028
Enrollment StartAug 2024
First PostedAug 2025
TodayJul 2026
Primary CompletionOct 2026
Study CompletionOct 2028
First PostedAug 8, 2025
Enrollment StartAug 15, 2024
Primary CompletionOct 31, 2026
Study CompletionOct 31, 2028
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 11 months agoPrimary completion in 4 months
Interventions
SYS6023drug
SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.